|
Gene: HPRT1 |
Gene summary for HPRT1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | HPRT1 | Gene ID | 3251 |
Gene name | hypoxanthine phosphoribosyltransferase 1 | |
Gene Alias | HGPRT | |
Cytomap | Xq26.2-q26.3 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | A0A140VJL3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3251 | HPRT1 | Tumor | Human | Cervix | CC | 4.99e-21 | 5.33e-01 | 0.1241 |
3251 | HPRT1 | sample3 | Human | Cervix | CC | 1.11e-30 | 5.69e-01 | 0.1387 |
3251 | HPRT1 | T3 | Human | Cervix | CC | 5.80e-30 | 5.68e-01 | 0.1389 |
3251 | HPRT1 | LZE2T | Human | Esophagus | ESCC | 2.44e-04 | 6.81e-01 | 0.082 |
3251 | HPRT1 | LZE4T | Human | Esophagus | ESCC | 4.23e-23 | 7.84e-01 | 0.0811 |
3251 | HPRT1 | LZE5T | Human | Esophagus | ESCC | 3.61e-05 | 6.61e-01 | 0.0514 |
3251 | HPRT1 | LZE7T | Human | Esophagus | ESCC | 3.96e-16 | 8.93e-01 | 0.0667 |
3251 | HPRT1 | LZE8T | Human | Esophagus | ESCC | 1.55e-16 | 5.05e-01 | 0.067 |
3251 | HPRT1 | LZE20T | Human | Esophagus | ESCC | 3.63e-12 | 2.74e-01 | 0.0662 |
3251 | HPRT1 | LZE22D1 | Human | Esophagus | HGIN | 7.77e-03 | 1.77e-01 | 0.0595 |
3251 | HPRT1 | LZE24T | Human | Esophagus | ESCC | 5.24e-38 | 1.08e+00 | 0.0596 |
3251 | HPRT1 | LZE21T | Human | Esophagus | ESCC | 1.94e-05 | 6.29e-01 | 0.0655 |
3251 | HPRT1 | LZE6T | Human | Esophagus | ESCC | 1.45e-21 | 1.09e+00 | 0.0845 |
3251 | HPRT1 | P1T-E | Human | Esophagus | ESCC | 5.73e-04 | 3.18e-01 | 0.0875 |
3251 | HPRT1 | P2T-E | Human | Esophagus | ESCC | 6.63e-42 | 8.83e-01 | 0.1177 |
3251 | HPRT1 | P4T-E | Human | Esophagus | ESCC | 3.90e-64 | 1.65e+00 | 0.1323 |
3251 | HPRT1 | P5T-E | Human | Esophagus | ESCC | 3.11e-64 | 1.35e+00 | 0.1327 |
3251 | HPRT1 | P8T-E | Human | Esophagus | ESCC | 8.79e-24 | 5.11e-01 | 0.0889 |
3251 | HPRT1 | P9T-E | Human | Esophagus | ESCC | 6.34e-26 | 7.66e-01 | 0.1131 |
3251 | HPRT1 | P10T-E | Human | Esophagus | ESCC | 2.34e-74 | 1.30e+00 | 0.116 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00706618 | Oral cavity | OSCC | leukocyte proliferation | 145/7305 | 318/18723 | 9.31e-03 | 3.33e-02 | 145 |
GO:001635810 | Oral cavity | OSCC | dendrite development | 113/7305 | 243/18723 | 1.00e-02 | 3.49e-02 | 113 |
GO:00466517 | Oral cavity | OSCC | lymphocyte proliferation | 131/7305 | 288/18723 | 1.41e-02 | 4.67e-02 | 131 |
GO:003465518 | Oral cavity | LP | nucleobase-containing compound catabolic process | 161/4623 | 407/18723 | 1.61e-11 | 1.15e-09 | 161 |
GO:001943916 | Oral cavity | LP | aromatic compound catabolic process | 176/4623 | 467/18723 | 1.96e-10 | 1.08e-08 | 176 |
GO:004427017 | Oral cavity | LP | cellular nitrogen compound catabolic process | 170/4623 | 451/18723 | 3.93e-10 | 2.02e-08 | 170 |
GO:004670016 | Oral cavity | LP | heterocycle catabolic process | 168/4623 | 445/18723 | 4.35e-10 | 2.20e-08 | 168 |
GO:190136116 | Oral cavity | LP | organic cyclic compound catabolic process | 180/4623 | 495/18723 | 3.11e-09 | 1.35e-07 | 180 |
GO:190165711 | Oral cavity | LP | glycosyl compound metabolic process | 43/4623 | 88/18723 | 7.80e-07 | 2.05e-05 | 43 |
GO:000912411 | Oral cavity | LP | nucleoside monophosphate biosynthetic process | 24/4623 | 42/18723 | 7.17e-06 | 1.37e-04 | 24 |
GO:000912312 | Oral cavity | LP | nucleoside monophosphate metabolic process | 36/4623 | 76/18723 | 1.46e-05 | 2.57e-04 | 36 |
GO:000911611 | Oral cavity | LP | nucleoside metabolic process | 31/4623 | 62/18723 | 1.46e-05 | 2.57e-04 | 31 |
GO:000912613 | Oral cavity | LP | purine nucleoside monophosphate metabolic process | 24/4623 | 44/18723 | 2.10e-05 | 3.46e-04 | 24 |
GO:000675319 | Oral cavity | LP | nucleoside phosphate metabolic process | 161/4623 | 497/18723 | 5.31e-05 | 7.39e-04 | 161 |
GO:00091271 | Oral cavity | LP | purine nucleoside monophosphate biosynthetic process | 14/4623 | 21/18723 | 5.81e-05 | 7.95e-04 | 14 |
GO:0009117110 | Oral cavity | LP | nucleotide metabolic process | 158/4623 | 489/18723 | 7.17e-05 | 9.49e-04 | 158 |
GO:00512591 | Oral cavity | LP | protein complex oligomerization | 85/4623 | 238/18723 | 8.81e-05 | 1.11e-03 | 85 |
GO:000916712 | Oral cavity | LP | purine ribonucleoside monophosphate metabolic process | 21/4623 | 41/18723 | 2.24e-04 | 2.41e-03 | 21 |
GO:000915611 | Oral cavity | LP | ribonucleoside monophosphate biosynthetic process | 18/4623 | 33/18723 | 2.26e-04 | 2.41e-03 | 18 |
GO:000916112 | Oral cavity | LP | ribonucleoside monophosphate metabolic process | 27/4623 | 58/18723 | 2.39e-04 | 2.54e-03 | 27 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012325 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa0123212 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa01232 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa00983 | Liver | Cirrhotic | Drug metabolism - other enzymes | 34/2530 | 80/8465 | 1.08e-02 | 3.57e-02 | 2.20e-02 | 34 |
hsa012321 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
hsa009831 | Liver | Cirrhotic | Drug metabolism - other enzymes | 34/2530 | 80/8465 | 1.08e-02 | 3.57e-02 | 2.20e-02 | 34 |
hsa012322 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa009832 | Liver | HCC | Drug metabolism - other enzymes | 54/4020 | 80/8465 | 2.25e-04 | 1.09e-03 | 6.08e-04 | 54 |
hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa009833 | Liver | HCC | Drug metabolism - other enzymes | 54/4020 | 80/8465 | 2.25e-04 | 1.09e-03 | 6.08e-04 | 54 |
hsa012324 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa0123211 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa0123221 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
hsa0123231 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HPRT1 | insertion | In_Frame_Ins | novel | c.213_214insCAGTTTCTACAGTCTCTCTTAATATTG | p.Gly71_Tyr72insGlnPheLeuGlnSerLeuLeuIleLeu | p.G71_Y72insQFLQSLLIL | P00492 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
HPRT1 | SNV | Missense_Mutation | c.229G>A | p.Asp77Asn | p.D77N | P00492 | protein_coding | deleterious(0.04) | possibly_damaging(0.767) | TCGA-EK-A2R7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
HPRT1 | SNV | Missense_Mutation | novel | c.583N>A | p.Tyr195Asn | p.Y195N | P00492 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HPRT1 | SNV | Missense_Mutation | rs387906725 | c.143N>A | p.Arg48His | p.R48H | P00492 | protein_coding | deleterious(0.01) | probably_damaging(0.965) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
HPRT1 | SNV | Missense_Mutation | rs137852484 | c.481N>T | p.Ala161Ser | p.A161S | P00492 | protein_coding | deleterious(0.01) | possibly_damaging(0.854) | TCGA-AG-3725-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HPRT1 | SNV | Missense_Mutation | novel | c.391N>G | p.Leu131Val | p.L131V | P00492 | protein_coding | deleterious(0) | benign(0.191) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HPRT1 | SNV | Missense_Mutation | novel | c.272N>T | p.Arg91Ile | p.R91I | P00492 | protein_coding | deleterious(0.01) | benign(0.015) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
HPRT1 | SNV | Missense_Mutation | novel | c.628N>A | p.Glu210Lys | p.E210K | P00492 | protein_coding | tolerated(0.07) | benign(0.013) | TCGA-AX-A1CR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
HPRT1 | SNV | Missense_Mutation | rs387906725 | c.143G>A | p.Arg48His | p.R48H | P00492 | protein_coding | deleterious(0.01) | probably_damaging(0.965) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HPRT1 | SNV | Missense_Mutation | c.260N>T | p.Arg87Ile | p.R87I | P00492 | protein_coding | deleterious(0.01) | benign(0.387) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3251 | HPRT1 | DRUGGABLE GENOME, ENZYME | NITROSOUREAS | 3328039 | ||
3251 | HPRT1 | DRUGGABLE GENOME, ENZYME | Mycophenolic Acid | |||
3251 | HPRT1 | DRUGGABLE GENOME, ENZYME | mycophenolic acid | |||
3251 | HPRT1 | DRUGGABLE GENOME, ENZYME | MERCAPTOPURINE | MERCAPTOPURINE | ||
3251 | HPRT1 | DRUGGABLE GENOME, ENZYME | MERCAPTOPURINE | MERCAPTOPURINE | ||
3251 | HPRT1 | DRUGGABLE GENOME, ENZYME | 3TC | LAMIVUDINE | 17358033 |
Page: 1 |